Alpert M A
Postgrad Med. 1987 May 1;81(6):257-67. doi: 10.1080/00325481.1987.11699832.
Vasodilator therapy represents an important step forward in the treatment of chronic left ventricular failure. Angiotensin converting enzyme (ACE) inhibitors appear to be the most versatile vasodilators, but selected direct-acting vasodilators, sympathetic inhibitors (prazosin), and possibly calcium channel antagonists (nifedipine and diltiazem) may be useful in certain situations. The bipyridine derivatives possess potent inotropic and vasodilating properties. The efficacy of intravenously administered amrinone and milrinone has been proven in the treatment of refractory left ventricular failure. Whether oral administration of milrinone or other bipyridine derivatives will prove to be safe and effective in the long-term treatment of chronic left ventricular failure remains uncertain.
血管扩张剂疗法是慢性左心室衰竭治疗方面向前迈出的重要一步。血管紧张素转换酶(ACE)抑制剂似乎是最通用的血管扩张剂,但某些直接作用的血管扩张剂、交感神经抑制剂(哌唑嗪)以及可能的钙通道拮抗剂(硝苯地平和地尔硫䓬)在特定情况下可能有用。双吡啶衍生物具有强大的正性肌力和血管舒张特性。静脉注射氨力农和米力农治疗难治性左心室衰竭的疗效已得到证实。米力农或其他双吡啶衍生物口服给药在慢性左心室衰竭的长期治疗中是否安全有效仍不确定。